Canadian Biosimilars Industry Urges Ontario To Switch
Biosimilars Canada Once Again Calls On Province To Follow Example Of Others
Executive Summary
Biosimilars Canada has renewed its call for Ontario to adopt a biosimilar switching policy in line with other Canadian provinces and territories, suggesting that Ontario alone could save CAD147m annually through such a scheme.
You may also be interested in...
Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy
Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.
Ontario Welcomes Biosimilar Switching Policy Following Extended Campaign
Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.
Biosimilars Canada Boss Calls For Ontario Switching Policy
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.